Onset, Maintenance, and Durability of Response with Dupilumab in Chronic Rhinosinusitis with Nasal Polyps

Conclusion: By W16, more dupilumab than pbo pts achieved clinically relevant response (onset), with the response maintained at W52 in >82% of dupilumab pts.

Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Bachert, C., Khan, A., Fokkens, W., Hopkins, C., Gevaert, P., Han, J., Hellings, P., Lee, S., Msihid, J., Nash, S., Siddiqui, S., Jacob-Nara, J., Deniz, Y., Rowe, P. Tags: 05.03 - Allergy and immunology Source Type: research